Metabolomic Approach to Identify Potential Biomarkers in KRAS-Mutant Pancreatic Cancer Cells

Area of Science:

• Oncology
• Metabolomics
• Molecular Biology

Background:

• Pancreatic cancer has a high mortality rate and limited treatment options.
• Oncogenic RAS mutations, particularly KRAS, are key drivers in pancreatic cancer.
• Understanding cancer cell metabolism is crucial for identifying therapeutic strategies.

Purpose of the Study:

• To investigate metabolomic differences in pancreatic cancer cells based on KRAS genetic status.
• To explore the impact of TRPML1 inhibition on the metabolomic profile of KRAS-mutant pancreatic cancer cells.
• To identify potential therapeutic targets and biomarkers for pancreatic cancer.

Main Methods:

• Untargeted metabolomics was performed on KRAS-wildtype (BxPC3) and KRAS-mutant (PANC1) pancreatic cancer cell lines.
• Principal component analysis and hierarchical condition trees were used for data analysis.
• Metabolite set enrichment analysis and KEGG pathway mapping were employed to identify significant metabolic alterations.
• TRPML1 inhibition was induced using ML-SI1 in PANC1 cells to assess its effect on metabolomics.

Main Results:

• 195 metabolites were differentially altered between KRAS-wildtype and KRAS-mutant cells, with distinct metabolic pathways identified (e.g., homocysteine degradation, taurine metabolism, lipid metabolism).
• TRPML1 inhibition in KRAS-mutant cells significantly altered the metabolomic profile, impacting pathways like arginine and proline metabolism.
• 17 significant metabolic pathways were associated with TRPML1 inhibition, and some metabolites showed opposite regulation compared to KRAS status, suggesting biomarker potential.

Conclusions:

• KRAS status significantly influences the metabolomic profile of pancreatic cancer cells.
• TRPML1 inhibition induces distinct metabolic changes in KRAS-mutant pancreatic cancer cells.
• Metabolic alterations driven by KRAS and TRPML1 offer potential avenues for novel pancreatic cancer therapies and diagnostics.